Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs.
SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs.
Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target.
"We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable."
Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts."
About Salipro Biotech ABSalipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins.
The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design.
To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs.
About Daewoong PharmaceuticalDaewoong Pharmaceutical (KRX: 069620.KS), established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities.
Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product.
View original content to download multimedia:https://www.prnewswire.com/news-releases/salipro-biotech-and-daewoong-pharmaceutical-announce-collaboration-agreement-to-advance-development-of-novel-therapeutics-302478350.html
SOURCE Daewoong Pharmaceutical Co., Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Bilderberg group meets in Sweden amid US-Europe tensions
STOCKHOLM (Reuters) -The annual Bilderberg Meeting kicks off in Sweden on Thursday, providing a private forum for discussion at a time when President Donald Trump has upended security and economic ties between the U.S. and Europe. The high-level networking event was formed in 1954 to foster dialogue between the U.S. and Europe. It does not invite media and delegates rarely speak about what has been discussed, triggering numerous conspiracy theories about their aims. NATO General Secretary Mark Rutte, Microsoft CEO Satya Nadella and Christopher Donahue, Commander of the U.S. Army Europe and Africa are among those on this year's delegate list, published by the organisers just ahead of the meeting. Swedish Prime Minister Ulf Kristersson will give a speech "on Sweden's and the EU's competitiveness and Sweden's support for Ukraine," his spokesperson told Reuters. Transatlantic relations top the agenda, with Ukraine, critical raw materials and AI also on the list, the organisers who also publish the names of the participants, said. Other than that, information is scarce. The organisers say the secrecy is to allow participants to be able to speak freely in an environment of trust. "There is no desired outcome, there is no closing statement, there are no resolutions proposed or votes taken, and the Meeting does not support any political party or viewpoint," the official website says. How much impact groups like Bilderberg actually have is hard to judge, according to Christina Garsten, professor at the Swedish Collegium for Advanced Study, who studies transnational think tanks. They aim to shape the broad political and corporate agenda. But if they are seen as having too much influence, they can be accused of being anti-democratic. "It's there that conspiracy theories can flower," she said. She dismissed the belief held by some that groups like Bilderberg make up a shadowy world government. "I think it's very much exaggerated," she said.
Yahoo
26 minutes ago
- Yahoo
Cytovale's Rapid Diagnostic Slashes Sepsis Mortality by 39%, Peer-Reviewed Study Confirms
Cytovale's IntelliSep® sepsis test highlights a new model for ED triage that's already delivering systemwide clinical and economic value Results of real-world study with 12,000+ patients published in the journal Healthcare SAN FRANCISCO, June 12, 2025 /PRNewswire/ -- One of the largest real-world studies of a sepsis diagnostic reveals that Cytovale's IntelliSep®, a U.S. Food and Drug Administration (FDA)-cleared rapid host response diagnostic, reduced the relative rate of sepsis mortality by 39%, shortened length of hospital stay and enabled more efficient resource allocation in the emergency department (ED). The study, "Impact of a Sepsis Quality Improvement Initiative on Clinical and Operational Outcomes," published in the peer-reviewed journal Healthcare, followed more than 12,000 patients over 12 months at Our Lady of the Lake Regional Medical Center (OLOLRMC), a 900-bed in-patient acute care facility and Level 1 trauma center in Baton Rouge, La. "This is the kind of data the medical field has been waiting for and the results represent a breakthrough in sepsis care," said Dr. Christopher Thomas, study author who serves as Vice President and Chief Quality Officer at Franciscan Missionaries of Our Lady Health System (FMOLHS) and is a critical care physician at Louisiana State University Health Sciences Center. "With this small operational change, we are able to save more lives, deliver better care faster and optimize use of hospital resources. It's a pivotal step forward in how emergency departments manage sepsis. With IntelliSep, we've discovered a new way to save lives." Key Study Findings 39% relative rate reduction in sepsis mortality, with non-sepsis mortality unchanged, validating the impact of IntelliSep on targeted triage. 0.76 day decrease in average hospital length of stay for sepsis patients, with strong implications for improved throughput and cost reduction. 40% decrease in blood culture usage in low risk patients and an 8% increase in high-risk cases, underscoring the ability of IntelliSep to help providers fine-tune diagnostic precision. Detecting Sepsis in Minutes, Bringing Speed and Confidence to the FrontlineSepsis is one of the most elusive and deadly conditions in modern medicine, responsible for nearly one in three hospital deaths in the United States. EDs often err on the side of caution, treating a wide range of incoming patients as potentially septic because there is a lack of reliable, objective methods for early risk assessment. Treating every patient as potentially septic, while understandable in a high-stakes environment like the ED, often results in unnecessary, non-beneficial interventions for patients who likely do not have sepsis. The strains on limited ED resources was a top concern for OLOLRMC when it implemented IntelliSep as part of a nurse-driven sepsis triage initiative designed to identify and rapidly triage patients at highest risk. IntelliSep is the first and only FDA-cleared diagnostic to aid in early sepsis detection in the ED. Using a routine blood draw, the test delivers results in about eight minutes. This helps clinicians to rule in or rule out sepsis even before clinical signs are fully visible, giving them greater confidence to determine which patients are in most urgent need of care. The combination of a rapid diagnostic and a protocolized workflow has yielded what the study authors describe as a "game-changing model" for health systems nationwide. "This is more than an innovation – it's a paradigm shift in how health systems are managing sepsis," said Dr. Hollis O'Neal, Medical Director of Research at OLOLRMC. "For decades, sepsis mortality rates have remained stagnant because we've lacked a fast, reliable way to catch sepsis early. This study proves that with speed, objectivity and accuracy at the point of triage, we can change outcomes before antibiotics are given or ICU beds are needed. That's where real transformation begins." Validated in One Hospital, Scaled Across the Health SystemSepsis is not just a clinical challenge, it's a financial one. For hospitals with more than 500 beds, annual sepsis-related costs can exceed $34 million. A bet on a new approach to sepsis care paid off for OLOLRMC. Reflecting its confidence in IntelliSep's clinical and operational impact at scale, the system's leadership has expanded IntelliSep across four additional sites within FMOLHS. "As health systems face mounting pressures to deliver efficient, effective care, adopting this precise, rapid method will be key to saving lives and controlling costs," Dr. Thomas added. "Those who embrace this approach position themselves at the forefront of sepsis care innovation." About Cytovale®Cytovale is committed to improving patient care by pioneering early detection technologies that assess immune activation to accelerate the time it takes to get from triage to life-saving therapies. Cytovale's U.S. Food and Drug Administration-cleared rapid sepsis diagnostic, IntelliSep®, leverages machine learning and advanced microfluidics to provide Emergency Department clinicians with an objective and highly sensitive early detection tool for sepsis. IntelliSep measures the dysregulated immune system response to infection that would indicate sepsis and generates results in about eight minutes using a standard blood draw. Cytovale is based in San Francisco and venture-backed by Norwest Venture Partners, Sands Capital and Global Health Investment Corporation (GHIC). For more information, visit and follow Cytovale on LinkedIn and X. View original content to download multimedia: SOURCE Cytovale Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Inuvo Reaffirms 25% Q2 YOY Growth Guidance and Completes 1:10 Reverse Stock Split
LITTLE ROCK, Ark., June 12, 2025 (GLOBE NEWSWIRE) -- Inuvo, Inc. (NYSE American: INUV), a leading provider of artificial intelligence-driven AdTech solutions, today announced that it was reaffirming its prior guidance that the Company was expecting revenue growth for the second quarter of not less than 25% on a year-over-year basis. The Company also completed a 1-for-10 reverse stock split of its outstanding common stock, as approved by shareholders at the Annual Meeting held on May 22, 2025. Inuvo's purpose in effectuating the reverse stock split is to improve the marketability and liquidity of its stock aiming to attract a broader range of institutional investors and analysts in support of its long-term growth strategy. Richard Howe, Chief Executive Officer of Inuvo, commented, 'Following two consecutive record-breaking quarters, we believe this strategic action will make our stock more accessible to institutional investors, many of whom are restricted from purchasing stocks trading below certain thresholds.' About Inuvo Inuvo®, Inc. (NYSE American: INUV) is a market leader in Artificial Intelligence built for advertising. Its IntentKey® AI solution is a first-of-its-kind proprietary and patented technology capable of identifying and actioning to the reasons why consumers are interested in products, services, or brands, not who those consumers are. To learn more, visit Safe Harbor / Forward-Looking Statements This press release includes certain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to qualify for the 'safe harbor' from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements include risks and uncertainties detailed in Inuvo, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, Inuvo's subsequent Quarterly Report on Form 10-Q for the period ended March 31, 2025, and Inuvo's other filings with the SEC. Inuvo cannot provide assurances that the assumptions upon which these forward-looking statements are based will prove to have been correct. Should one of these risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those expressed or implied in any forward-looking statements, and investors are cautioned not to place undue reliance on these forward-looking statements, which are current only as of this date. Inuvo does not intend to update or revise any forward-looking statements made herein or any other forward-looking statements as a result of new information, future events or otherwise. Inuvo further expressly disclaims any written or oral statements made by a third party regarding the subject matter of this press release. Inuvo Company Contact: Wally Ruiz Chief Financial Officer Tel (501) 205-8508
